Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

被引：0
|
作者：
Ken-ichi Fujita
Yuichi Ando
Fumio Nagashima
Wataru Yamamoto
Hisashi Eodo
Kazuhiro Araki
Keiji Kodama
Toshimichi Miya
Masaru Narabayashi
Yasutsuna Sasaki
机构：
[1] Saitama Medical University,Department of Clinical Oncology
[2] Saitama Medical University,Project Research Laboratory, Research Center for Genomic Medicine, Saitama Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Irinotecan; SN-38; Polymorphism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：515 / 522
页数：7
相关论文
共 50 条
  • [41] PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity
    Fontaine, Shaun D.
    Santi, Angelo D.
    Reid, Ralph
    Smith, Philip C.
    Ashley, Gary W.
    Santi, Daniel V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 225 - 229
  • [42] Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
    Mirkov, S.
    Ramirez, J.
    Zhang, W.
    Chen, P.
    Das, S.
    Liu, W.
    Ratain, M. J.
    Innocenti, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S61 - S61
  • [43] Rapid analysis of UDP-glucuronosyltransferase polymorphisms (UGT1A1*28, UGT1A6*2 and UGT1A7*3) using real-time PCR
    Möhrle, B
    Köhle, C
    Bock, KW
    Schwab, M
    Wernet, D
    Münzel, PA
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R160 - R160
  • [44] Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28
    Tian, Chuan
    Ying, Haifeng
    Zhuang, Rongyuan
    Zhang, Xiaowei
    Lu, Hongmin
    Wang, Hui
    Wang, Shuowen
    Li, Qi
    Wang, Chungang
    Cai, Xun
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6217 - 6226
  • [45] PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity
    Shaun D. Fontaine
    Angelo D. Santi
    Ralph Reid
    Philip C. Smith
    Gary W. Ashley
    Daniel V. Santi
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 225 - 229
  • [46] SORAFENIB IS AN INHIBITOR OF UGT1A1 BUT IS METABOLIZED BY UGT1A9: IMPLICATIONS OF UGT1A GENETIC VARIANTS ON SORAFENIB EXPOSURE AND SORAFENIB-INDUCED HYPERBILIRUBINEMIA
    Peer, C. J.
    Sissung, T. M.
    Jain, L.
    Woo, S.
    Gardner, E. R.
    Kirkland, C. T.
    English, B. C.
    Federspiel, J.
    Figg, W. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S46 - S47
  • [47] Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or*60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese
    Saito, Yoshiro
    Sai, Kimie
    Maekawa, Keiko
    Kaniwa, Nahoko
    Shirao, Kuniaki
    Hamaguchi, Tetsuya
    Yamamoto, Noboru
    Kunitoh, Hideo
    Ohe, Yuichiro
    Yamada, Yasuhide
    Tamura, Tomohide
    Yoshida, Teruhiko
    Minami, Hironobu
    Ohtsu, Atsushi
    Matsumura, Yasuhiro
    Saijo, Nagahiro
    Sawada, Jun-ichi
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (02) : 272 - 276
  • [48] Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer
    Fukuda, Minoru
    Okumura, Manabu
    Iwakiri, Tomomi
    Arimori, Kazuhiko
    Honda, Takuya
    Kobayashi, Kazuma
    Senju, Hiroaki
    Takemoto, Shinnosuke
    Ikeda, Takaya
    Yamaguchi, Hiroyuki
    Nakatomi, Katsumi
    Matsuo, Nobuko
    Mukae, Hiroshi
    Ashizawa, Kazuto
    THORACIC CANCER, 2018, 9 (01) : 51 - 58
  • [49] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Fei-fei Han
    Chang-long Guo
    Dan Yu
    Jin Zhu
    Li-li Gong
    Guang-run Li
    Ya-li Lv
    He Liu
    Guang-yu An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 779 - 788
  • [50] Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase in a phase II study of capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Carlini, LE
    Meropol, NJ
    Chen, YM
    McGarry, C
    Hill, T
    Gold, P
    Blanchard, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 275S - 275S
12345